Houston Wire & Cable Company (Nasdaq:HWCC) announced that Chuck Sorrentino, Chief Executive Officer, and Jim Pokluda, President, are presenting at William Blair & Company’s 31st Annual Growth Stock Conference on Tuesday, June 14th at 1:30 p.m. Central Time at the Four Seasons Hotel in Chicago. A webcast of this presentation will be available through the following link: http://williamblair.rmxpres.com/webcast/data/Houston2011/main.htm, the accompanying slides will be available through the Events and Presentations section of the Company’s Investor Relations website at http://ir.houwire.com
Houston Wire & Cable Company, through its subsidiaries, distributes specialty wire and cable products, as well as provides related services to the United States electrical distribution market.
Power3 Medical Products Inc. (PWRM)
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro�, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro�, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
Alzheimer’s disease, or AD, is a progressive, incurable disease of the brain caused by the degeneration and eventual death of neurons (nerve cells) in several areas of the brain.
Alzheimer’s disease is now considered a very serious public health problem because of the growing numbers of people who are affected by it, the increasing length of their lives, and the direct and indirect costs of their care. It is estimated that four million people in the United States had AD as of 2000; with 360,000-400,000 new cases identified every year. One person in ten over the age of 65 has AD, and nearly 50% of those over 85 have the disease. Unless a cure or preventive treatment is discovered, 14 million Americans will have Alzheimer’s by 2050.
The NuroPro Blood Test of Power3 Medical Products, Inc is a diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease. Early detection of these diseases would allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.
For more information about Power3 Medical Products, Inc., please visit http://www.power3medical.com
National Health Partners, Inc. (NHPR)
National Health Partners, Inc. is a national healthcare savings organization that provides discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called “CARExpress.” CARExpress is one of the largest networks of hospitals, doctors, dentists, pharmacists and other healthcare providers in the country and is comprised of over 1,000,000 medical professionals that belong to such PPOs as CareMark and Aetna. The company’s primary target customer group is the 47 million Americans who have no health insurance of any kind. The company’s secondary target customer group includes the millions of Americans who lack complete health insurance coverage. The company is headquartered in Horsham, Pennsylvania.
Hospital care in the U.S. is about twice as costly as in other industrialized economies, health care market is experiencing a large influx of companies who are taking advantage of technology to use in a growing field of healthcare communications and health-record management; at a basic level, this means using technology to manage health records and share information with a patient’s physician or other approved health care providers and caregivers — including family members. Health care is expensive in the United States, as health care costs average over 10% of GDP for most developed nations.
National Health Partners, Inc. announced the successful launch of a new, major marketing campaign that has caused the number of the company’s new member enrollments to increase sharply.
While only in its infancy, the campaign has been so successful that National Health Partners is on pace to more than triple the number of new members generated recently compared to the number of new members generated in the past. This growth should continue to build at an equally fast pace, especially over the next several months, as new facets of the marketing campaign are rolled out. Thereafter, the campaign will continue to generate an increasing number of new members for the company indefinitely into the future.
NHPR expects to achieve significant profits during 2011 driven by the substantial sales growth that this campaign may provide.
Please visit its website at www.nationalhealthpartners.com
DexCom, Inc. (Nasdaq:DXCM) announced that Terrance Gregg, Chief Executive Officer, is an Ernst & Young Entrepreneur Of The Year� 2011 San Diego Award finalist. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. Mr. Gregg was selected as a finalist from nearly 100 nominations by a panel of independent judges. Award winners will be announced at a special gala event on June 16th at the Hyatt Regency La Jolla.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Monotype Imaging Holdings Inc. (Nasdaq:TYPE) has introduced the 22-font Neue Haas Grotesk� typeface family - the original Helvetica� design - into the company’s Linotype� collection. The release of Neue Haas Grotesk marks Monotype Imaging’s digital debut of a typeface that was first designed for handset composition using metal type in the late 1950s. Soon after, the design began to undergo revisions yet went on to great success. It eventually became arguably the world’s most famous typeface, used widely in branding, advertising and signage - but under a different name.
Monotype Imaging Holdings Inc., through its subsidiaries, provides text imaging solutions worldwide. The company involves in developing, marketing, and licensing technologies and fonts for displaying and printing digital text.
No comments:
Post a Comment